Celcuity’s Revtorpyk (gedatolisib) won a key FDA approval for HR-positive/HER2-negative locally advanced or metastatic breast cancer patients without a PIK3CA mutation after progression on endocrine therapy. The company is positioning the small molecule as a first-in-class approach via the PAM pathway inhibitor mechanism, but investor reaction was muted by disclosure around a later-than-expected launch window and prescribing-details questions. Celcuity’s regulatory win adds a new targeted option to the crowded breast cancer landscape, with Revtorpyk slated for initial commercial ramp-up in the third quarter of 2026. The approval narrows eligibility to a biomarker-defined subgroup, underscoring the continued importance of companion-logic and genomic testing in U.S. launches. Separately, FDA’s broader June review also included a step-change in cell therapy: the agency’s approvals comprised Tregzi (Orca-T), described as the first approved allogeneic Treg-based cell therapy used with myeloablative conditioning to improve chronic graft-versus-host disease-free survival in matched-donor hematopoietic stem cell transplantation settings.